The HDAC1 Knockout SK-HEP-1 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population for investigating histone deacetylase 1 (HDAC1) function. Derived from the human hepatic adenocarcinoma cell line SK-HEP-1, this product offers a loss-of-function model through pooled gene disruption, enabling unbiased functional studies without clonal selection artifacts.
The SK-HEP-1 cell line, originally isolated from the ascites of a liver adenocarcinoma patient, is a widely used model for hepatic sinusoidal endothelium. It retains key characteristics of hepatocellular carcinoma, including aberrant signaling pathways, and is frequently employed in cancer biology, metastasis research, and drug screening.
HDAC1 encodes a class I histone deacetylase that catalyzes deacetylation of histone H3 and H4 tails, leading to chromatin compaction and transcriptional repression. It functions within large corepressor complexes, such as those formed with SIN3A, CoREST, and the NuRD components MTA2, RBBP4, RBBP7, and CHD4. Upstream regulation by CK2 and transcription factors TP53 and MYC modulates HDAC1 activity, which in turn directly affects the acetylation status of downstream targets including TP53, E2F1, and STAT3. Through these interactions, HDAC1 interfaces with the Wnt/??-catenin (CTNNB1), Notch (NOTCH1), TGF-?? (SMAD2), and p53 (TP53/CDKN1A) pathways, governing cell cycle progression, apoptosis, and differentiation.
In the SK-HEP-1 background, HDAC1 deletion is expected to relieve repression of tumor suppressive genes and may impair proliferation, survival, and epithelial-mesenchymal transition. This knockout population thus offers a powerful tool to dissect HDAC1??s specific contributions to liver adenocarcinoma biology, including its roles in chromatin remodeling and gene regulation that drive hepatocellular carcinoma phenotypes within a sinusoidal endothelial setting.
Researchers can employ this product for chromatin immunoprecipitation?CqPCR (ChIP-qPCR) to map histone acetylation landscapes, RNA-seq or RT-qPCR to profile transcriptomic changes, and functional assays such as apoptosis and migration tests. The polyclonal knockout cells also provide an isogenic platform for HDAC inhibitor screening, enabling assessment of compound efficacy and identification of synthetic lethal interactions. For more details, please contact Ascent Research.
